Osteopontin, angiogenesis and multiple myeloma

Leukemia

Volumn 19, Issue 12, 2005, Pages 2203-2205

  Cheriyath, V ^a   Hussein, M A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN; TRANSCRIPTION FACTOR RUNX2;

BONE MARROW; DISEASE COURSE; GENE FUNCTION; HUMAN; MULTIPLE MYELOMA; NONHUMAN; NOTE; ONCOGENE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

EID: 28544439284     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403978     Document Type: Note

References (39)

1. Colla S, Morandi F, Lazzaretti M, Rizzato R, Lunghi P, Bonomini S et al. Human myeloma cells express the bone regulating gene RUNX2/CBFA1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 2006 (in press).
2. Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C et al. Proangiogenic properties of human myeloma cells: Production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 2003; 102: 638-645.
3. Giuliani N, Colla S, Morandi F, Rizzoli V. Angiopoietin-1 and myeloma-induced angiogenesis. Leuk Lymphoma 2005; 46: 29-33.
4. Inman CK, Shore P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 2003; 278: 48684-48689.
5. Wai PY, Kuo PC. The role of Osteopontin in tumor metastasis. J Surg Res 2004; 121: 228-241.
6. Zheng H, Guo Z, Ma Q, Jia H, Dang G. Cbfa1/osf2 transduced bone marrow stromal cells facilitate bone formation in vitro and in vivo. Calcif Tissue Int 2004; 74: 194-203.
7. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin - a molecule for all seasons. QJM 2002; 95: 3-13.
8. Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 1985; 232: 715-724.
9. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979; 16: 885-893.
10. Hussein MA, Juturi JV, Lieberman I. Multiple myeloma: Present and future. Curr Opin Oncol 2002; 14: 31-35.
11. Hussein MA. New treatment strategies for multiple myeloma. Semin Hematol 2004; 41 (4 Suppl 7): 2-8.
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
13. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503-508.
14. Asosingh K, De Raeve H, Menu E, Van Riet I, Van Marck E, Van Camp B et al. Angiogenic switch during 5T2MM murine myeloma tumorigenesis: Role of CD45 heterogeneity. Blood 2004; 103: 3131-3137.
15. Giuliani N, Colla S, Rizzoli V. Angiogenic switch in multiple myeloma. Hematology 2004; 9: 377-381.
16. Bellamy WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol 2001; 28: 551-559.
17. Bellamy WT. Vascular endothelial growth factor as a target opportunity in hematological malignancies. Curr Opin Oncol 2002; 14: 649-656.
18. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98: 428-435.
19. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: Evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004; 104: 1159-1165.
20. Saeki Y, Mima T, Ishii T, Ogata A, Kobayashi H, Ohshima S et al. Enhanced production of osteopontin in multiple myeloma: Clinical and pathogenic implications. Br J Haematol 2003; 123: 263-270.
21. Chellaiah MA, Kizer N, Biswas R, Alvarez U, Strauss-Schoenberger J, Rifas L et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 2003; 14: 173-189.
22. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 1998; 101: 1468-1478.
23. Rittling SR, Matsumoto HN, McKee MD, Nanci A, An XR, Novick KE et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 1998; 13: 1101-1111.
24. Yoshitake H, Rittling SR, Denhardt DT, Noda M. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA 1999; 96: 8156-8160.
25. Ishijima M, Rittling SR, Yamashita T, Tsuji K, Kurosawa H, Nifuji A et al. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med 2001; 193: 399-404.
26. Standal T, Borset M, Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 2004; 26: 179-184.
27. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion. Blood 2004; 104: 2484-2491.
28. Standal T, Hjorth-Hansen H, Rasmussen T, Dahl IM, Lenhoff S, Brenne AT et al. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica 2004; 89: 174-182.
29. Senger DR, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L. Adhesive properties of osteopontin: Regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell 1994; 5: 565-574.
30. Senger DR, Perruzzi CA. Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim Biophys Acta 1996; 1314: 13-24.
31. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol 1999; 52: 189-196.
32. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S et al. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 2000; 287; 860-864.
33. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
34. Ponta H, Sherman L, Herrlich PA. CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4: 33-45.
35. Rudy W, Hofmann M, Schwartz-Albiez R, Zoller M, Heider KH et al. The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: Each one individually suffices to confer metastatic behavior. Cancer Res 1993; 53: 1262-1268.
36. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-754.
37. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89: 755-764.
38. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89: 765-771.
39. Ito Y. Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 2004; 23: 4198-4208.